Pancreatic Cancer Research

ResearcherAmsterdam University Medical CentersActive in the last 2 years

Eran van Veldhuisen

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-5664-2286; OpenAlex author ID A5058683209. Sources: OpenAlex.

Their work

Papers
19 (first author 3, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
124
Papers, trials and grants by year

2018: 1 paper · 2019: 3 papers · 2020: 3 papers · 2021: 1 paper · 2022: 1 paper · 2023: 3 papers · 2024: 3 papers · 2025: 3 papers · 2026: 1 paper

Papers 19

  1. Surgical outcomes from nationwide implementation of the international best practice for locally advanced pancreatic cancer (PREOPANC-4) study. Co-author DOI 10.1093/bjs/znag075↗
  2. Adjuvant Chemotherapy After Resection of Localized Pancreatic Adenocarcinoma Following Preoperative FOLFIRINOX. Co-author DOI 10.1001/jamaoncol.2024.5917↗
  3. Validation of the PANAMA Score for Survival and Benefit of Adjuvant Therapy in Patients With Resected Pancreatic Cancer after Neoadjuvant FOLFIRINOX. Co-author DOI 10.1097/sla.0000000000006650↗
  4. Nationwide implementation of the international multidisciplinary best-practice for locally advanced pancreatic cancer (PREOPANC-4): study protocol. Co-author DOI 10.1186/s12885-025-13554-w↗
  5. Metformin boosts antitumor immunity and improves prognosis in upfront resected pancreatic cancer: an observational study. Co-author DOI 10.1093/jnci/djae070↗
  6. Nationwide Use and Outcome of Surgery for Locally Advanced Pancreatic Cancer Following Induction Chemotherapy. Co-author DOI 10.1245/s10434-023-14650-6↗
  7. ASO Author Reflections: Nationwide Experience on Locally Advanced Pancreatic Cancer Surgery After Induction Chemotherapy in the Netherlands: A Stepping Stone f… Co-author DOI 10.1245/s10434-023-14704-9↗
  8. Quantitative analysis of contribution of mild and moderate hyperthermia to thermal ablation and sensitization of irreversible electroporation of pancreatic can… Co-author DOI 10.1016/j.jtherbio.2023.103619↗
  9. Surgical and Oncological Outcomes After Preoperative FOLFIRINOX Chemotherapy in Resected Pancreatic Cancer: An International Multicenter Cohort Study. Co-author DOI 10.1245/s10434-022-12387-2↗
  10. Intraoperative Ultrasound During Surgical Exploration in Patients with Pancreatic Cancer and Vascular Involvement (ULTRAPANC): A Prospective Multicenter Study. Co-author DOI 10.1245/s10434-023-13112-3↗
  11. Added value of 3T MRI and the MRI-halo sign in assessing resectability of locally advanced pancreatic cancer following induction chemotherapy (IMAGE-MRI): pros… First author DOI 10.1007/s00423-022-02653-y↗
  12. Readily available biomarkers predict poor survival in metastatic pancreatic cancer. First author DOI 10.1080/1354750x.2021.1893814↗
  13. Evaluation of Adjuvant Chemotherapy in Patients With Resected Pancreatic Cancer After Neoadjuvant FOLFIRINOX Treatment. First author DOI 10.1001/jamaoncol.2020.3537↗
  14. Value of CT-Guided Percutaneous Irreversible Electroporation Added to FOLFIRINOX Chemotherapy in Locally Advanced Pancreatic Cancer: A Post Hoc Comparison. Co-author DOI 10.1016/j.jvir.2020.02.024↗
  15. Percutaneous Irreversible Electroporation in Locally Advanced and Recurrent Pancreatic Cancer (PANFIRE-2): A Multicenter, Prospective, Single-Arm, Phase II Stu… Co-author DOI 10.1148/radiol.2019191109↗
  16. Added value of intra-operative ultrasound to determine the resectability of locally advanced pancreatic cancer following FOLFIRINOX chemotherapy (IMAGE): a pro… Co-author DOI 10.1016/j.hpb.2019.02.017↗
  17. Neoadjuvant FOLFIRINOX in Patients With Borderline Resectable Pancreatic Cancer: A Systematic Review and Patient-Level Meta-Analysis. Co-author DOI 10.1093/jnci/djz073↗
  18. Locally Advanced Pancreatic Cancer: Work-Up, Staging, and Local Intervention Strategies. Co-author DOI 10.3390/cancers11070976↗
  19. Added value of CA19-9 response in predicting resectability of locally advanced pancreatic cancer following induction chemotherapy. Co-author DOI 10.1016/j.hpb.2018.01.001↗

Closest collaborators

The 25 strongest of 124 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Marc G. Besselink · 12 shared papers, 2018–2025 · strength 1.24
  2. Krijn P. van Lienden · 7 shared papers, 2018–2023 · strength 0.71
  3. Johanna W. Wilmink · 8 shared papers, 2018–2022 · strength 0.69
  4. Hanneke W.M. van Laarhoven · 6 shared papers, 2018–2025 · strength 0.61
  5. Jantien A. Vogel · 4 shared papers, 2018–2023 · strength 0.42
  6. Bas Groot Koerkamp · 4 shared papers, 2019–2025 · strength 0.36
  7. Ignace H. J. T. de Hingh · 3 shared papers, 2019–2023 · strength 0.34
  8. Thilo Hackert · 3 shared papers, 2019–2025 · strength 0.30
  9. Marco Del Chiaro · 3 shared papers, 2019–2025 · strength 0.30
  10. Quisette P. Janssen · 3 shared papers, 2019–2025 · strength 0.28
  11. Thomas F. Stoop · 2 shared papers, 2022–2025 · strength 0.27
  12. Martijn Ruben Meijerink · 3 shared papers, 2019–2020 · strength 0.27
  13. Morgan Bonds · 2 shared papers, 2020–2025 · strength 0.22
  14. Giuseppe Malleo · 2 shared papers, 2020–2025 · strength 0.22
  15. Alberto Balduzzi · 2 shared papers, 2020–2025 · strength 0.22
  16. Tobias Keck · 2 shared papers, 2020–2025 · strength 0.22
  17. Asif Halimi · 2 shared papers, 2020–2025 · strength 0.22
  18. Adnan A. Alseidi · 2 shared papers, 2020–2025 · strength 0.22
  19. Daniel Pietrasz · 2 shared papers, 2020–2025 · strength 0.22
  20. Johan Gagnière · 2 shared papers, 2020–2025 · strength 0.22
  21. Stijn R. van Roessel · 2 shared papers, 2020–2025 · strength 0.22
  22. Frederik Christiaan Berrevoet · 2 shared papers, 2020–2025 · strength 0.22
  23. Kevin C. Conlon · 2 shared papers, 2020–2025 · strength 0.22
  24. Isabella M. Frigerio · 2 shared papers, 2020–2025 · strength 0.22
  25. Giovanni Butturini · 2 shared papers, 2020–2025 · strength 0.22

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.